Doctronic 為人工智慧遠距醫療項目獲得大額融資
Doctronic secures major funding for AI-powered telemedicine
紐約的新創公司Doctronic在近期籌集了4000萬美元的B輪融資，此舉可能重新定義現代醫學。
In a move that could redefine modern medicine, New York-based startup Doctronic has secured $40 million in Series B funding.
該公司成立於2023年，旨在透過「人工智慧原生」(AI-native)平台解決美國醫療保健的可及性危機。
Founded in 2023, the company aims to tackle the U.S. healthcare access crisis by using an AI-native platform.
與基礎的症狀檢查工具不同，Doctronic利用一套獨特的多代理人系統，模擬臨床大型巡迴查房來制定診斷，隨後由人類醫生進行驗證。
Unlike basic symptom checkers, Doctronic utilizes a unique multi-agent system where specialized AI agents simulate clinical grand rounds to formulate diagnoses, which are then validated by human doctors.
該公司在美國全境50州運作，已獲得極大的採納率，每週擁有超過30萬名獨立訪客。
Operating in all 50 U.S. states, the company has seen massive adoption, with over 300,000 unique visitors weekly.
近日，Doctronic在猶他州啟動了一項試點計畫，允許人工智慧處理常規處方箋續配，達成了監管里程碑。
Recently, Doctronic hit a regulatory milestone by launching a pilot program in Utah, allowing AI to handle routine prescription refills.
儘管面臨關於安全漏洞的一些審視——公司堅持這些漏洞並不影響其受監管的試點計畫——Doctronic仍站在邁向人工智慧自主照護轉型的前沿。
Despite facing some scrutiny regarding safety vulnerabilities—which the company maintains do not impact their regulated pilot—Doctronic remains at the forefront of the shift toward AI-autonomous care.
透過填補「Google醫師」與傳統初級照護之間的缺口，Doctronic證明了人工智慧可以為醫療結果承擔法律責任，為更有效率、更可及的未來鋪平道路。
By bridging the gap between "Dr.
